Emerging studies suggest Retatrutide , a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may represent a promising development for obesity management . Early human trials have indicated considerable reductions in abdominal tissue, conceivably surpassing existing body composition therapies . Nevertheless , add